genOway and Merck Expand Strategic Alliance on CRISPR/Cas9 Technology

Lyon, France, January 7, 2020 /PRNewswire/ -- genOway, a publicly listed company and leader in the development of genetically engineered research models, today announced a significant milestone: the expansion of its strategic alliance with Merck, a leading science and technology company and pioneer in genome editing.

In December 2018, genOway obtained from Merck KGaA a global exclusive license to the foundational CRISPR/Cas9 portfolio in the rodent field (covering all applications involving rodent cells or animals). Today, the two companies are further strengthening their collaboration by entering into an additional licensing agreement that grants genOway non-exclusive rights to commercialize the development and use of all other animal cell models for its customers’ internal research and commercial development.

“We are pleased to expand our partnership with Merck. Merck’s intellectual property portfolio is continuously growing and expanding. Merck is now recognized as a foundation CRISPR Leading Provider of Intellectual Property.Alexandre Fraichard, Founder and Chief Operating Officer of genOway, stated, “This additional license will allow genOway Better serve our customers by providing comprehensive, multifunctional solutions and essential intellectual property to help accelerate their research.”

Merck and genOway have jointly identified research areas in which they can combine their respective technologies and expertise to develop and validate new CRISPR/Cas9-related products and solutions. Merck’s CRISPR patent integration technology serves as a powerful entry point for the development and launch of innovations.

genOway Introduction

genOway (Euronext Growth®: ALGEN; ISIN: FR0004053510) is a biotechnology company operating in 28 countries across Europe, Asia, and North America, with collaborations involving more than 260 research institutions and 80 biopharmaceutical companies. genOway’s development is built upon an extensive portfolio of proprietary technology platforms and robust intellectual property, combining patents and licensing agreements. The company has entered into numerous commercial contracts with leaders in the pharmaceutical industry (such as BMS, Janssen, Novartis, and Pfizer) as well as with prestigious academic research centers, including King’s College London and the University of Manchester in the United Kingdom; Harvard University, the California Institute of Technology, and the National Institutes of Health in the United States; the Pasteur Institute in France; and the German National Genome Research Network and the Max Planck Institute in Germany.

www.genOway.com

Business Contact Information:
Sandrine Carteau
licensing@genoway.com  
+33-43-76-54-100